PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million

PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, announced the closing of a Series B extension, bringing the company’s total Series B financing to $77 million.

WilmerHale advised PAQ Therapeutics on the transaction.

The Series B extension builds on PAQ’s previously announced Series B financing. Proceeds from the financing will support the ongoing Phase 1 development of PT0253, PAQ’s KRAS G12D degrader, and PT0511, a pan-KRAS degrader.

The WilmerHale team was led by partner Andrea Sorrentino and included partner Stuart Falber and associate Amy O’Connell, with assistance from attorney Heidi Treiber and senior paralegal Cynthia Sullivan.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel